|[October 09, 2013]
Glancy Binkow & Goldberg LLP Encourages Investors of Achillion Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact the Firm
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Achillion
Pharmaceuticals, Inc. ("Achillion" or the "Company") (NASDAQ:ACHN)
concerning possible violations of federal securities laws. Investors
with losses of $250,000 or more are encouraged to contact the firm for
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at firstname.lastname@example.org
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
Achillion is a biopharmaceutical company engaged in the discovery,
development and commercialization of anti-infective drug therapies in
the United States and internationally. The Company focuses on the
development of antiviral therapies for the treatment of chronic
hepatitis C viral (HCV) infection. One of the Company's lead
cliical-stage drug candidates is sovaprevir - a treatment for chronic
HCV infection - designed for use in combination with other therapeutic
products with complementary mechanisms of action. The investigation is
related to allegations that the Company misrepresented or failed to
disclose that sovaprevir did not interact well with other drugs commonly
used to treat hepatitis or patients infected with both hepatitis and
human immunodeficiency virus (HIV).
On July 1, 2013, Achillion disclosed that the Food and Drug
Administration instituted a clinical hold on sovaprevir after elevations
in liver enzymes were noted in a "Phase I healthy subject drug-drug
interaction study evaluating the effects of concomitant administration
of sovaprevir with ritonavir-boosted atazanavir." Subsequently, on
September 27, 2013, the Company disclosed that the FDA had continued its
clinical hold on sovaprevir after the agency concluded that "removal of
the clinical hold is not warranted."
If you purchased Achillion shares between April 21, 2012 and September
27, 2013, if you have information or would like to learn
more about these claims or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ InfoTech Spotlight's Homepage ]